Transcatheter Mitral Valve Repair Versus Transcatheter Mitral Valve Replacement in Patients with Mitral insufficiency

Aims. Mitral regurgitation (MR) is the most prevalent form of valvular heart disease. Transcatheter mitral valve repair (TMVr) and transcatheter mitral valve replacement (TMVR) have recently emerged as alternatives to open heart surgical repair or replacement. However, studies on the comparative outcomes of TMVr and TMVR are limited. This study aims to compare the demographics, complications and outcomes of TMVr and TMVR based on a real-world investigation of the National Inpatient Sample (NIS) database.Methods and Results. From 2016-2018 in the NIS database, a total of 210 and 3370 patients who underwent TMVR and TMVr, respectively, were selected. The mean age of the patients was 75.99 years (TMVr) and 69.6 years (TMVR) ( p < 0.01). The mortality of patients who received TMVR was higher compared to that of patients who were treated with TMVr (8.1 vs . 1.9%, p < 0.01). The patients who underwent TMVR were more likely to suffer perioperative complications including blood transfusions (16.2 vs . 5.0%, p < 0.01) and acute kidney injury (22.9 vs . 13.3%, p < 0.01). The average cost of treatment was higher (USD $278864 vs . USD $216845, p < 0.01), and the average duration of hospitalization was longer (8.73 vs . 4.17 d, p < 0.01) for TMVR compared to TMVr. When taking into account perioperative comorbidities and other factors, TMVR was associated with a worse adjusted in-hospital mortality (odds ratio [OR], 3.307 [95% CI, 1.533-7.136]; p < 0.01).Conclusion. TMVr is associated with lower mortality, peri-procedural morbidity, and resource use compared to TMVR. A patient-centered approach can help guide decisionmaking about the choice of intervention for the individual patient and more studies evaluating the long-term outcomes and durability of TMVR are needed at present.(c) 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.